Across TCGA pan-cancer cohorts, RPL22P4 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL22P4’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL22P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL22P4 is over-expressed in tumor.

BRCA, LUSC, and HNSC are the cancer types where RPL22P4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL22P4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	+0.019	.018	4	view →
LUSC	All	All	+0.027	.016	3	view →
HNSC	Male	All	+0.046	.029	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPL22P4 RNA expression & survival · all RPL22P4 data types